These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The potential for organ-preserving treatment in large uveal melanoma].
    Author: Terent'eva LS, Fokin VP.
    Journal: Oftalmol Zh; 1989; (6):338-41. PubMed ID: 2622597.
    Abstract:
    As compared with enucleation, organ-preserving treatment (photocoagulation, local excision, radiotherapy) of uveal melanoma doesn't worsen the prognosis for the patient's life. However, it was used chiefly for tumors of stages T1-T2, the prominence of the tumor not exceeding 4-5 mm. The purpose of the present communication was a study of the possibility of organ-preserving beta radiotherapy for treatment of uveal melanomas T3, the prominence of the tumor exceeding 5 mm. A new Soviet beta applicator (ruthenium-106, rhodium-106) was used for treatment of 21 patients with melanoma T3N0M0, who had refused enucleation. Average summary doses on the surface of the sclera were 1561 +/- 41 Gr. Clinical results (the follow-up period ranging from 12 to 20 months) were the following: total resorption of the tumor--3 cases; the volume of the tumor reduced by 1/2 and more--9 cases, by less than 1/2--7 cases; the size of the tumor remained unchanged--2 cases. Enucleation was made in 2 patients 3 and 4 months after radiation. The results obtained have shown beta therapy to be effective in some cases of uveal melanoma T3, this allowing to widen indications to organ-preserving treatment.
    [Abstract] [Full Text] [Related] [New Search]